Literature DB >> 18514581

Circadian distribution of generalized tonic-clonic seizures associated with murine succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Lee S Stewart1, Kirk J Nylen, Michael A Persinger, Miguel A Cortez, K Michael Gibson, O Carter Snead.   

Abstract

Human succinic semialdehyde dehydrogenase (SSADH) deficiency is an autosomal recessive disorder of GABA metabolism associated with motor impairment and epileptic seizures. Similarly, mice with targeted deletion of the Aldh5a1 gene (Aldh5a1(-/-)) exhibit SSADH deficiency and seizures early in life. These seizures begin as absence seizures the second week of life, but evolve into generalized convulsive seizures that increase in severity and become lethal during the fourth postnatal week. The seizures are alleviated and survival is prolonged when the mutant animals are weaned onto a ketogenic diet (KD). The persistence of spontaneous, recurrent, generalized tonic-clonic seizures in KD-treated adult Aldh5a1(-/-) mice allowed us to quantify their daily (circadian) distribution using a novel behavioral method based on the detection of changes in movement velocity. Adult KD-treated Aldh5a1(-/-) mice exhibited a seizure phenotype characterized by fits of wild running clonus accompanied by jumping and bouncing. These hypermotor seizures were largely spontaneous and occurred daily in a nonrandom pattern. The seizure rhythm showed a peak shortly after dark phase onset (2008 hours) with near-24-hour periodicity. Age-matched wild-type littermates showed no evidence of abnormal motor behavior. These new data suggest that generalized tonic-clonic seizures in Aldh5a1(-/-) mice are more frequent during a specific time of day and will provide useful information to clinicians for the treatment of seizures associated with human SSADH deficiency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18514581      PMCID: PMC2574901          DOI: 10.1016/j.yebeh.2008.04.012

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  31 in total

1.  CNS inputs to the suprachiasmatic nucleus of the rat.

Authors:  K E Krout; J Kawano; T C Mettenleiter; A D Loewy
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

2.  A neural circuit for circadian regulation of arousal.

Authors:  G Aston-Jones; S Chen; Y Zhu; M L Oshinsky
Journal:  Nat Neurosci       Date:  2001-07       Impact factor: 24.884

3.  Sex difference in psychological behavior changes induced by long-term social isolation in mice.

Authors:  Ming Guo; Chun Fu Wu; Wen Liu; Jing Yu Yang; Duo Chen
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-01       Impact factor: 5.067

4.  Purification from human brain and some properties of two NADPH-linked aldehyde reductases which reduce succinic semialdehyde to 4-hydroxybutyrate.

Authors:  C D Cash; M Maitre; P Mandel
Journal:  J Neurochem       Date:  1979-12       Impact factor: 5.372

5.  Inhibition of the substantia nigra suppresses absences and clonic seizures in audiogenic rats, but not tonic seizures: evidence for seizure specificity of the nigral control.

Authors:  C Deransart; B T Lê-Pham; E Hirsch; C Marescaux; A Depaulis
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

6.  Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase.

Authors:  B M Hogema; M Gupta; H Senephansiri; T G Burlingame; M Taylor; C Jakobs; R B Schutgens; W Froestl; O C Snead; R Diaz-Arrastia; T Bottiglieri; M Grompe; K M Gibson
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

7.  Anticonvulsant action of GABA receptor blockade in the nigrotectal target region.

Authors:  P Dean; K Gale
Journal:  Brain Res       Date:  1989-01-16       Impact factor: 3.252

Review 8.  Developmental and genetic audiogenic seizure models: behavior and biological substrates.

Authors:  K C Ross; J R Coleman
Journal:  Neurosci Biobehav Rev       Date:  2000-08       Impact factor: 8.989

9.  Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor.

Authors:  O C Snead
Journal:  J Neurochem       Date:  2000-11       Impact factor: 5.372

10.  Seizure evolution and amino acid imbalances in murine succinate semialdehyde dehydrogenase (SSADH) deficiency.

Authors:  M Gupta; M Polinsky; H Senephansiri; O C Snead; E E W Jansen; C Jakobs; K M Gibson
Journal:  Neurobiol Dis       Date:  2004-08       Impact factor: 5.996

View more
  5 in total

Review 1.  Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance.

Authors:  Kyung-Jin Kim; Phillip L Pearl; Kimmo Jensen; O Carter Snead; Patrizia Malaspina; Cornelis Jakobs; K Michael Gibson
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

Review 2.  Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

Review 3.  Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men.

Authors:  P L Pearl; K M Gibson; M A Cortez; Y Wu; O Carter Snead; I Knerr; K Forester; J M Pettiford; C Jakobs; W H Theodore
Journal:  J Inherit Metab Dis       Date:  2009-01-28       Impact factor: 4.982

4.  Aberrant GABA(A) receptor-mediated inhibition in cortico-thalamic networks of succinic semialdehyde dehydrogenase deficient mice.

Authors:  Adam C Errington; K Michael Gibson; Vincenzo Crunelli; David W Cope
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

Review 5.  Understanding the Molecular Mechanisms of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD): Towards the Development of SSADH-Targeted Medicine.

Authors:  Henry H C Lee; Gabrielle E McGinty; Phillip L Pearl; Alexander Rotenberg
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.